Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | HTR2B | P41595 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11860229 | 0.95 | KCNH2 (0.56) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11863099 | 0.95 | HRH1 (0.56) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11866929 | 0.92 | KCNH2 (0.56) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL6452266 | 0.90 | KCNH2 (0.51) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL18609071 | 0.90 | OPRK1 (0.49) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL1968862 | 0.89 | LMNA (0.64) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11859793 | 0.88 | HTR1A (0.52) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL9075109 | 0.84 | OPRM1 (0.46) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL9073468 | 0.84 | SIGMAR1 (0.55) | LMNADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL1969399 | 0.84 | LMNA (0.51) | KCNH2LMNAHRH1DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108195962-B | Method for detecting and separating related substances of terfenadine | 江苏联环药业股份有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| EP-0563134-B1 | AGENTS FOR POTENTIATING THE EFFECTS OF ANTITUMOR AGENTS AND COMBATING MULTIPLE DRUG RESISTANCE | WELLCOME FOUND (GB) | 1996-06-19 | — | — | EP | disclosed |
| US-5416091-A | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | BURROUGHS WELLCOME CO. (US) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | KCNH2 1413/4885LMNA 1841/4885HRH1 1562/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | KCNH2 1413/4885LMNA 1841/4885HRH1 1562/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | KCNH2 1413/4885LMNA 1841/4885HRH1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.